At Axela, we provide comprehensive protein array solutions, offering both Forward Phase Protein Arrays (FPPA) and Reverse Phase Protein Arrays (RPPA) to meet diverse research needs.
Forward Phase Protein Arrays are ideal for high-throughput biomarker discovery and validation. Antibodies are immobilized on the array surface to capture proteins from complex biological samples, enabling the simultaneous detection and quantification of hundreds of proteins. This approach is particularly powerful for profiling signaling pathways, studying disease-related biomarkers, and screening therapeutic targets.
Reverse Phase Protein Arrays are optimized for quantitative protein expression and phosphorylation analysis across large sample sets. In this format, protein lysates from multiple samples are spotted onto the array, and detection is carried out with high-specificity antibodies. RPPA is widely used in translational research, oncology, and clinical studies to track pathway activation, monitor treatment responses, and identify predictive biomarkers.
Forward Phase Protein Array (FPPA)
Strengths:
High-throughput profiling with the ability to measure hundreds of proteins simultaneously
Excellent for biomarker discovery, validation, and pathway analysis
Sensitive detection of low-abundance proteins from complex samples
Scalable and customizable panels tailored to research needs
Applications:
Biomarker identification in oncology, immunology, and neurology
Drug discovery and screening for therapeutic target validation
Pathway profiling to study protein networks and disease mechanisms
Multiplex analysis of serum, plasma, cell culture supernatants, and tissue lysates
Reverse Phase Protein Array (RPPA)
Strengths:
Highly quantitative and reproducible across large sample sets
Requires only small amounts of starting material
Sensitive to post-translational modifications such as phosphorylation
Suitable for comparative studies across many patient or experimental samples
Applications:
Clinical research: monitoring treatment responses and patient stratification
Oncology studies: tracking signaling pathway activation and therapeutic resistance
Translational research: bridging preclinical and clinical data
Large-scale studies involving hundreds of samples for biomarker verification
With Axela’s protein array services, you receive comprehensive, ready-to-use datasets that ensure both depth and clarity. Each project delivers a structured spreadsheet with sample identifiers and quantified expression levels for every target protein, provided in raw, normalized, and median-centered formats. To aid interpretation, we supply paired heatmaps—both supervised and unsupervised—that visualize protein expression patterns across your samples. A detailed study report accompanies every dataset, summarizing results and highlighting key biological insights, making your data immediately actionable for downstream research.
Accuracy and reproducibility are central to our workflow. To validate array results, we perform parallel analyses using Western blot, the gold standard for protein detection. The example shown demonstrates AKT phosphorylation across 14 cancer cell lines, analyzed under identical culture conditions by both RPPA and Western blot. Results are presented as relative fluorescence intensity (RFI) values from RPPA, directly compared with raw Western blot images. This head-to-head validation confirms that our protein array platform delivers robust, quantitative, and trustworthy results you can rely on for critical decisions.
Have questions? Ask Axela — we’re here to help.
📧 info@axelabio.com